Receive a FREE Mesothelioma Treatment
Information Packet

Mesothelioma

Doxorubicin With or Without P-30 Protein in Treating Patients With Malignant Mesothelioma

Doxorubicin With or Without P-30 Protein in Treating Patients With Malignant Mesothelioma

Background:
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether doxorubicin plus P-30 protein is more effective than doxorubicin alone in treating patients with malignant mesothelioma. This is a randomized phase III trial to compare the effectiveness of doxorubicin with or without P-30 protein in treating patients with malignant mesothelioma.

Location/Contact Information:
Alabama
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, 35294-3300, United States;
Recruiting
Francisco Robert, MD, FACP 205-934-5077

California
Sidney Kimmel Cancer Center, San Diego, California, 92121, United States; Recruiting
Dana Glenn, MD 619-450-5990

Tower Hematology Oncology Medical Group, Los Angeles, California, 90048, United States; Recruiting
Solomon I. Hamburg, MD, PhD 310-289-2840

Colorado
University of Colorado Cancer Center, Denver, Colorado, 80010, United States;
Recruiting
Karen Kelly, MD 303-315-8801
karen.kelly@uchsc.edu

Florida
Oncology-Hematology Group of South Florida, Miami, Florida, 33176, United States;
Recruiting
Paul Robert Kaywin, MD 305-595-2141

Illinois
University of Chicago Cancer Research Center, Chicago, Illinois, 60637, United States;
Recruiting
Nicholas J. Vogelzang, MD 773-702-6743 nvogelza@medicine.bsd.uchicago.edu

Indiana
CCOP - Northern Indiana CR Consortium, South Bend, Indiana, 46601, United States;
Recruiting
Jose A. Bufill, MD 800-284-7370

Kentucky
Kentuckiana Cancer Institute, Louisville, Kentucky, 40202, United States; Recruiting
Shawn Glisson, MD 502-561-8200

New Jersey
Somerset Medical Center, Somerville, New Jersey, 08876, United States; Recruiting
Hen-Vai Wu, MD 908-685-2200

New York
Herbert Irving Comprehensive Cancer Center, New York, New York, 10032, United States; Recruiting
Robert N. Taub, MD, PhD 212-305-4076

Pennsylvania
Presbyterian Medical Center of Philadelphia, Philadelphia, Pennsylvania, 19104-2699, United States;
Recruiting
Kenneth M. Algazy, MD 215-662-8947
Kenneth.Algazy@uphs.upenn.edu

Tennessee
Thompson Cancer Survival Center, Knoxville, Tennessee, 37916, United States;
Recruiting
Samuel Spence McCachren, MD 865-541-1720

Texas
Lone Star Oncology, Austin, Texas, 78759, United States;
Recruiting
John J. Costanzi, MD 512-343-2103
drjjjc@aol.com

University of Texas - MD Anderson Cancer Center, Houston, Texas, 77030-4009, United States;
Recruiting
Ralph G. Zinner, MD 713-792-6161

Virginia
Center for Cancer Care, Charlottesville, Virginia, 22902, United States; Recruiting
Stefan M. Gorsch, MD 434-982-8410

Virginia Oncology Associates - Hampton, Hampton, Virginia, 23666, United States;
Recruiting
Scott Kruger, MD 757-827-9400

Germany
Allgemeines Krankenhaus, Hamburg, DOH-21075, Germany; Recruiting
Eckhard Kaukel 49 40 79212241
Asklepios Fachkliniken Munchen - Gauting, Munich, DOH-82131, Germany; Recruiting
Joachim Von Pawel, MD 49-89-8579-12011

Hospital Grosshansdorf, Grosshansdorf, D-22927, Germany;
Recruiting
Christian Peschel, MD 49-4102-601-360

Study chairs or principal investigators
Stanislaw Marian Mikulski, MD, Study Chair
Alfacell